Scottsdale resident donates $1 million to TGen pancreatic cancer initiative
April 21, 2017
Dr. Von Hoff said that TGen, through the Virginia G. Piper Cancer Center at Scottsdale Healthcare and its other PCRT partners, are making progress in the quest to end this cancer: "We are to deliver a knockout punch by combining the best treatments we have against the disease. The contributions of Roger Magowitz represent significant acceleration toward our goal of finding better treatments, and ultimately a cure."
The other clinical trial sites are:
Virginia Piper Cancer Institute, Minneapolis, Minn., where the principal investigator is Dr. John Seng: "We are one of the nation's leading pancreatic cancer treatment centers. The new Seena clinical trial will allow patients to take a more active role in their health care, gain access to new drugs, treatments and disease management practices, and contribute to medical research."
Evergreen Hematology & Oncology, Spokane, Wash., where the principal investigator is Dr. Stephen Anthony: "As the former Chief Medical Officer of TGen Drug Development, I know how meticulously this study will be organized and conducted, using every efficiency possible to reach patients with the safest and most effective compounds possible."
Roy and Patricia Disney Family Cancer Center, Burbank, Calif., where the principal investigator is Dr. Peter Rosen: "The Roy and Patricia Disney Family Cancer Center brings innovative clinical trials to the San Fernando Valley, an underserved population of close to 3 million inhabitants. In addition to Phase I (drug development) trials and an Adolescent and Young Adult (AYA) program, we are committed to a frontal attack on pancreas cancer, the nation's fourth leading cause of cancer mortality. The Seena trial exemplifies that commitment."
Source: The Translational Genomics Research Institute